106 related articles for article (PubMed ID: 1962618)
1. Nizatidine versus placebo in gastroesophageal reflux disease: a 12-week, multicenter, randomized, double-blind study.
Cloud ML; Offen WW; Robinson M
Am J Gastroenterol; 1991 Dec; 86(12):1735-42. PubMed ID: 1962618
[TBL] [Abstract][Full Text] [Related]
2. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 12-week, multicentre, randomised, double-blind study.
Cloud ML; Offen WW; Robinson M
Br J Clin Pract Suppl; 1994 Nov; 76():3-10. PubMed ID: 7794701
[TBL] [Abstract][Full Text] [Related]
3. Nizatidine versus placebo in gastro-oesophageal reflux disease: a 6-week, multicentre, randomised, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.
Cloud ML; Offen WW
Br J Clin Pract Suppl; 1994 Nov; 76():11-9. PubMed ID: 7794700
[TBL] [Abstract][Full Text] [Related]
4. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease.
Armstrong D; Paré P; Pericak D; Pyzyk M;
Am J Gastroenterol; 2001 Oct; 96(10):2849-57. PubMed ID: 11695354
[TBL] [Abstract][Full Text] [Related]
5. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group.
Sabesin SM; Berlin RG; Humphries TJ; Bradstreet DC; Walton-Bowen KL; Zaidi S
Arch Intern Med; 1991 Dec; 151(12):2394-400. PubMed ID: 1746996
[TBL] [Abstract][Full Text] [Related]
6. Nizatidine versus placebo in gastroesophageal reflux disease. A six-week, multicenter, randomized, double-blind comparison. Nizatidine Gastroesophageal Reflux Disease Study Group.
Cloud ML; Offen WW
Dig Dis Sci; 1992 Jun; 37(6):865-74. PubMed ID: 1587191
[TBL] [Abstract][Full Text] [Related]
7. Treatment of erosive reflux oesophagitis: a double-blind multicentre trial with nizatidine 300 mg b.i.d. versus placebo.
Dobrilla G; Chilovi F; Tafner G; Vantini I; Bernardi A; Gentilini R; Fedrizzi F; Manfrini R; Steiner H; Mon M
Ital J Gastroenterol; 1992; 24(6):338-41. PubMed ID: 1515660
[TBL] [Abstract][Full Text] [Related]
8. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children.
Orenstein SR; Gremse DA; Pantaleon CD; Kling DF; Rotenberg KS
Clin Ther; 2005 Apr; 27(4):472-83. PubMed ID: 15922820
[TBL] [Abstract][Full Text] [Related]
9. Onset of relief of symptoms of gastroesophageal reflux disease: post hoc analysis of two previously published studies comparing pantoprazole 20 mg once daily with nizatidine or ranitidine 150 mg twice daily.
Haag S; Holtmann G
Clin Ther; 2010 Apr; 32(4):678-90. PubMed ID: 20435237
[TBL] [Abstract][Full Text] [Related]
10. A double-blind, placebo-controlled study of the effectiveness and safety of nizatidine in the prevention of postprandial heartburn.
Spiegel JE; Thoden WR; Pappas K; Fratarcangelo P; Furey SA
Arch Intern Med; 1997 Jul; 157(14):1594-9. PubMed ID: 9236562
[TBL] [Abstract][Full Text] [Related]
11. Cimetidine QID and BID in rapid heartburn relief and healing of lesions in gastroesophageal reflux disease.
Palmer RH; Miller DM; Hedrich DA; Karlstadt RG
Clin Ther; 1993; 15(6):994-1001. PubMed ID: 8111819
[TBL] [Abstract][Full Text] [Related]
12. Ranitidine is effective therapy for erosive esophagitis.
Euler AR; Murdock RH; Wilson TH; Silver MT; Parker SE; Powers L
Am J Gastroenterol; 1993 Apr; 88(4):520-4. PubMed ID: 8470632
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of nizatidine and famotidine for maintenance therapy of erosive esophagitis.
Hamamoto N; Hashimoto T; Adachi K; Hirakawa K; Ishihara S; Inoue H; Taniura H; Niigaki M; Sato S; Kushiyama Y; Suetsugu H; Miyake T; Kinoshita Y
J Gastroenterol Hepatol; 2005 Feb; 20(2):281-6. PubMed ID: 15683433
[TBL] [Abstract][Full Text] [Related]
14. Heartburn severity does not predict disease severity in patients with erosive esophagitis.
Fennerty MB; Johnson DA
MedGenMed; 2006 Apr; 8(2):6. PubMed ID: 16926745
[TBL] [Abstract][Full Text] [Related]
15. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
Larson JD; Patatanian E; Miner PB; Rayburn WF; Robinson MG
Obstet Gynecol; 1997 Jul; 90(1):83-7. PubMed ID: 9207819
[TBL] [Abstract][Full Text] [Related]
16. Metoclopramide in gastroesophageal reflux disease: rationale for its use and results of a double-blind trial.
McCallum RW; Fink SM; Winnan GR; Avella J; Callachan C
Am J Gastroenterol; 1984 Mar; 79(3):165-72. PubMed ID: 6367434
[TBL] [Abstract][Full Text] [Related]
17. Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Robinson M; McFarland M; Sabesin S; Lehman GA; Castell D
Am J Gastroenterol; 1997 Mar; 92(3):429-37. PubMed ID: 9068463
[TBL] [Abstract][Full Text] [Related]
18. Ranitidine therapy for gastroesophageal reflux disease. Results of a large double-blind trial.
Sontag S; Robinson M; McCallum RW; Barwick KW; Nardi R
Arch Intern Med; 1987 Aug; 147(8):1485-91. PubMed ID: 3307670
[TBL] [Abstract][Full Text] [Related]
19. Sucralfate used as adjunctive therapy in patients with severe erosive peptic esophagitis resulting from gastroesophageal reflux.
Herrera JL; Shay SS; McCabe M; Peura DA; Johnson LF
Am J Gastroenterol; 1990 Oct; 85(10):1335-8. PubMed ID: 2220725
[TBL] [Abstract][Full Text] [Related]
20. [Symptomatic therapy with famotidine in non-erosive gastro-esophageal reflux. Results of an open multicenter study].
Heckers H; Lübbecke F
Arzneimittelforschung; 1995 Apr; 45(4):499-504. PubMed ID: 7779150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
